Biden’s War on Drugs

The White House would have you believe President Biden is fighting a war on drug prices, but they won’t tell you what’s he’s doing is really a war on drugs. This issue was first discussed in two blog posts nearly a year ago, The Real Cost of Lowering Drug Prices and Cancer Drug Breakthroughs Threatened.

Fast forward to today when The Wall Street Journal editorial board wrote Drug Price Controls Mean Slower Cures. They say, “The Inflation Reduction Act (IRA) is the worst legislation to pass Congress in many years, and its drug price controls are especially harmful. On Tuesday President Biden announced the first 10 drugs for controls, and he’s exaggerating the benefits while ignoring the larger damage.”

The IRA legislation requires the Centers for Medicare and Medicaid Services to “negotiate” prices for the top-spending Medicare drugs, starting with 10 this year and a total of 60 by 2029. The law sets the drug price ceiling at between 25% and 60% of its list price, with no price floor. Drug makers that don’t participate or reject the government’s price will incur a crippling daily excise tax that starts at 186% and eventually climbs to 1,900% of the drug’s daily revenues. WSJ’s editors say, “This is extortion, not a negotiation.”

In the first round of 2023, the Biden Administration is targeting drugs that treat common conditions such as Bristol Myers Squibb’s blood thinner Eliquis, Boehringer Ingelheim and Eli Lilly’s diabetes drug Jardiance, Johnson & Johnson’s blood thinner Xarelto, Amgen’s rheumatoid arthritis drug Enbrel and Novo Nordisk’s insulin Novolog. The President proclaimed “This plan is a key part of Bidenomics.” 

But WSJ editors say this plan relies on deceptive advertising, like his other command-and-control government plans. Start with the claim that the 10 drugs accounted for $50.5 billion – or about 20% of “gross” costs for Medicare’s Part D drug program. “Gross” spending excludes the discounts that drug makers pay Part D plans for higher placement on formularies. Medicare drug prices are already negotiated by insurers, and Part D net spending is about half Medicare’s “gross” costs. The Administration also overstates the rise in prescription drug costs. Medicare spending on prescription drugs has grown less than for hospital and physician services in the last decade. Total U.S. out-of-pocket spending on prescription drugs in nominal dollars is lower than it was in 2003 and accounted for only 1% of the $4.25 trillion the U.S. spent on healthcare in 2021.

The real problem is the impact the IRA will have on new drug innovation. This legislation will discourage investment in new generics and biosimilars because their manufacturers could later be undercut by government price controls on brand drugs. That means Americans may end up paying more for prescription drugs thanks to the IRA. The law will also give companies the incentives to launch drugs at higher prices and raise prices for privately insured patients to compensate for the Medicare cuts. That means the 218 million Americans with private insurance will pay more for drugs. Call it the Private Insurance Inflation Act.

President Biden also claims this will decrease prices “for up to 9 million seniors.” That sounds good if you’re campaigning for senior votes. But WJS editors say this claim is also inflated. Several drugs on its list will soon lose market exclusivity and could face competition from generics that reduce prices without government intervention. Now those generics might not be developed or launched.

The IRA encourages drug makers to slow-walk development of treatments for smaller populations since Food and Drug Administration approval would start the clock on eligibility for price controls. The law will also discourage drug makers from studying and launching drugs for new indications, as AstraZeneca explained in a lawsuit last week. A study in the Journal of the American Medical Association this month estimated that about a quarter of FDA-approved orphan drugs were developed for at least one follow-on indication. Under the IRA, many wouldn’t have been. There’s no such thing as a free drug.

What will be the impact of the IRA on research and development of new drugs?

A University of Chicago study estimated that the drug price controls would reduce research and development by $663 billion through 2039 and result in 135 fewer new drugs being approved. These are among the IRA’s unseen costs, which will include lives that could have been saved or extended by new treatments that were delayed or never developed.

I’ll bet that won’t be included in President Biden’s next campaign speech.

Single-Payer Healthcare Wastes Money and Time – Part V

(Author’s Note: This is the sixth, and last, in two series of posts explaining what’s wrong with single-payer, government-run healthcare. Recent interviews with medical school and public-health policy students have shown this information is desperately needed to warn our youth of the evils of this form of healthcare. This series was first published in October, 2017 and is re-published here.)

 

Chris Conover, Duke economist, has given us four reasons, hidden costs, thus far:

  • $625 Billion to $1.1 Trillion in deadweight losses from new taxes (Part I)
  • $453 to $626 Billion in additional waste (Part II)
  • $152 to $914 Billion in costs resulting from rationing (Part III)
  • $23 to $152 Billion in social losses from reduced innovation (Part IV)
  • Thus the hidden costs of Sanders’ plan are $1.24 Trillion to $2.8 Trillion per year ($3,800 to $8,500 per U.S. resident)

 

This should be plenty of reasons to oppose the Sanders Medicare For All plan. But even if someone should try to refute these numbers, as someone certainly will, Conover gives us a fifth reason we cannot dismiss – our nation cannot afford it.

What will the Sanders Plan actually cost?

The Sanders campaign of 2016 used the projections of Gerard Friedman, economist at The University of Massachusetts – Amherst, to claim his plan would actually reduce healthcare expenditures by $6.3 Trillion over ten years (13.3%). These numbers have been challenged by other economists, including the liberal think-tank, The Urban Institute.

  • Ken Thorpe, Emory University economist and advisor to the Clinton health plan, estimates the Sanders plan would cost $24.7 Trillion over a decade and add a budget shortfall of greater than $1 Trillion per year.
  • The Urban Institute calculated the Sanders plan would increase federal spending by $32 Trillion over a decade (232.7%), an increase in healthcare spending of $6.6 Trillion (26%).
  • Conover has critiqued the Friedman report and found he underestimated the cost by $16.6 Trillion by failure to calculate deadweight losses and the cost of moral hazards.
  • Avik Roy, Manhattan Institute economist, critiqued the Friedman report and found the Sanders plan would increase the federal deficit between $14.4 Trillion and $19 Trillion.

Current Unfunded Liabilities

In 2015, the U.S. had a fiscal gap of $210 Trillion. Economists calculate this number by taking the sum of the current federal debt plus the present value of all future tax revenues minus all future federal program costs. When that number is a negative one, there is a fiscal gap or unfunded liability.

      Federal debt + future tax revenues – future federal programs expenses

Present value means it is the additional amount Americans need to have in the bank today earning interest at the U.S. Treasury bill rate in order to finance all our future promises. Health programs such as Medicare, Medicaid and ObamaCare are huge sources of such enormous unfunded liabilities (55% in 2012).

  • State and local governments add $38 Trillion to this number
  • $210 Trillion amounts to $644,000 per U.S. resident
  • $210 Trillion is more than 11 times the GDP in 2016
  • The total wealth in all U.S. households is only about $94.8 Trillion
  • To close this gap would have required raising all federal taxes by 58.5% or cutting federal spending by 37.7%.

 

These numbers are staggering to behold, too much for our comprehension. Therefore it is no wonder that politicians have been “kicking the can down the road”, avoiding the harsh reality of dealing with these deficits. But what they are really doing is stealing from their children and grandchildren who will be forced to pay for their reckless spending.

It’s time to stop the madness. Here is the reality this generation must face. If the Urban Institute calculations are correct, and they are certainly a liberal think-tank unlikely to oppose liberal policies, the Sanders Medicare For All Act would only make this situation worse. It would increase the fiscal gap by a minimum of $61 Trillion!

The Bottom Line

  • The Sanders plan will impose hidden costs ranging from $1.25 Trillion to as much as $2.8 Trillion per year.
  • The Sanders plan will increase the fiscal gap by a minimum of $61 Trillion.
  • America cannot afford this expensive new entitlement.
  • No amount of “taxing the rich” will pay for this.
  • This will require us to steal from our children and grandchildren – which is morally unacceptable.
  • We can anticipate long waiting lines and lower quality care.
  • In contrast, market-oriented systems rely on markets to ensure universal access to high quality care at an affordable price.

     

Single-Payer Healthcare Wastes Money and Time – Part IV

 

(Author’s Note: This is the fifth in two series of posts explaining what’s wrong with single-payer, government-run healthcare. Recent interviews with medical school and public-health policy students have shown this information is desperately needed to warn our youth of the evils of this form of healthcare. This series was first published in October, 2017 and is re-published here.)

 

Chris Conover, Duke economist, has given us three reasons thus far including:

  • Hidden costs of $1.1 Trillion in deadweight losses in 2017 alone
  • More than half a Trillion dollars of added waste to our system
  • Rationing of care costs ranging from $152 to $194 Billion in 2017 alone

 

Medical Innovation Adverse Effects

The fourth reason to oppose single-payer healthcare systems is the adverse effects it will have on medical innovation. Conover says the U.S. is by far the world’s leader in medical innovation. George Mason University economist Tyler Cowen put it this way over a decade ago: “The American health care system, high expenditures and all, is driving innovation for the entire world.”

The U.S. leadership in biomedical innovation is indisputable. According to Thomas Boehm, Medical Director at Jerini AG, the availability of funding “is the single most important factor explaining the dominant role of the U.S. in innovative research.”

  • From 1988 – 2003, the S. invested more than 5 times as much as the EU in private biotechnology companies. (see graphic below)
  • As of 2012, U.S. biomedical R&D spending amounted to 0.76% of GDP, compared to only 0.46% in Europe and 0.35% in Canada. Single-payer Canada devotes less than half as much of its economy to biomedical R&D as the U.S. does. (see graphic below)
  • Although the U.S. economy accounts for only 16.2% of world GDP (2012), the S. accounted for 44.4% of biomedical R&D in the world.
  • Private industry R&D accounts for 59% of total U.S. spending.

 

Pharmaceutical R&D Spending

The U.S. dominance in pharmaceutical spending is even greater than in biomedical research. The major reason for this is the U.S. is the lone major industrialized country not to impose pharmaceutical price controls. Profits in the U.S. pharmaceutical industry are approximately four times higher than in other countries. These increased profits are directly linked to pharmaceutical R&D spending.

How much would pharmaceutical innovation be reduced under a single-payer healthcare system such as “Medicare For All?”

Economist John Vernon has done simulations that show that if pharmaceutical prices in the U.S. were regulated (controlled) as other countries do, this would lead to a decline in industry R&D between 23.4 and 32.7percent.

The current social benefit economists calculate for the consumers of pharmaceuticals is about $1.4 Trillion per year. New drugs are estimated to amount to $100 Billion of this benefit in 2017. If there were a decline in industry R&D between 23% and 33%, the expected loss of social benefit would be about $23 Billion to $33 Billion under a Canadian-style system with price controls.

Increased Life Expectancy

There is another adverse effect of single-payer healthcare on pharmaceutical innovation. Columbia University professor Frank Lichtenberg has calculated the impact on life expectancy as a result of “New Molecular Entities” (NMEs) – new drugs approved. He estimates every NME increases life expectancy an average of 0.17 years every year.

Thus far in 2017, the FDA has approved 34 NMEs; in 2016 it approved 22 NMEs. Using the 2016 data, if single-payer price controls resulted in this number being reduced by 23 to 33%, it would imply the annual loss of 5 to 7 NMEs a year – which would reduce life expectancy by 1.5 to 2.0 months. Since there are nearly 4 million births a year in the U.S. that implies a loss of 482,000 to 692,000 years of life that might other wise been gained had innovation remained at current levels. If each life year is assumed to be worth $100,000, that represents a loss of $48 to $69 Billion.

How much would other medical innovation be reduced under Medicare For All?

Pharmaceutical R&D constitutes less than half (45.5%) of all U.S. medical research spending. If the cost-effectiveness of the other 54.5% were identical to pharmaceuticals, the aggregate social cost of lost innovation would range from a low of $50 Billion to a high of $152 Billion. 

This other medical innovation actually exceeds pharmaceuticals in importance. Of the six most important innovations of the last 25 years, only two – ACE inhibitors for control of high blood pressure and statins to lower cholesterol levels – have been drugs. The others include MRI scans, CT scans, Balloon angioplasty and coronary artery bypass grafts.  Imagine if these life-changing innovations had never happened as a result of adopting a single-payer healthcare system.

 

Author’s Note: Stay tuned for the fifth reason, and last in the two series of posts on the subject of Single-Payer Healthcare.